World

Smokers under 30 need photo IDs to buy tobacco products

Aug 30, 2024

Washington [US], August 30: The U.S. Food and Drug Administration has mandated more people show photo identification when buying tobacco products, as the health regulator raised the age verification requirement by three years.
As part of a rule finalized by the agency on Thursday, the FDA now requires retailers to verify the age of anyone under 30 when they buy tobacco products, from under 27 previously.
The FDA also said retailers cannot sell tobacco products via vending machine in places where individuals under 21 are present or permitted to enter, from 18 years previously.
The United States has been cracking down on the use of tobacco over the past few years to curb preventable deaths from smoking and other products, as well as stop the use of e-cigarettes by minors.
The World Health Organization had said in May tobacco companies were trying to hook a new generation on nicotine by actively targeting them via social media, sports and music festivals.
The FDA had raised the minimum age for tobacco use to 21 years from 18 in 2019.
According to the American Lung Association, smoking kills more than 480,000 people per year in the United States, making it the leading preventable cause of death in the country.
Source: Fijian Broadcasting Cooperation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025